Shawn Bird, MD
Neurology · Philadelphia, PANPI 1770517427
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,850 of the $9,422 with a category attached, or 93.9%. AstraZeneca accounts for 99.8% of it on its own, with 1 other manufacturer making up the rest. 2025 is the largest year on record at $9,191, more than ten times the $110 reported in 2019.
Across 11 payments — averaging $856.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$9K
- Johnson & Johnson$18
Across 16 payments — averaging $9340.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$149K
What the payments were for
- Consulting fees$8,85094%
- Food & beverage$5546%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 10 | $9,404 |
| Johnson & Johnson | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,422 in reported general payments places this provider in the 75th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvgartEfgartigimod Alfa-Fcab | 43 | $1,344,975 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 40 | $1,157,914 |
| FirdapseAmifampridine Phosphate | 15 | $876,673 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 48 | $654,427 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 15 | $245,838 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 20 | $229,514 |
| Mycophenolate Mofetil | 191 | $43,644 |
| Pyridostigmine Bromide | 126 | $13,776 |
| Azathioprine | 62 | $5,012 |
| Prednisone | 170 | $1,382 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 15 | $956 |
| Gabapentin | 24 | $457 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 13 | $375 |
| Sodium Chloride0.9 % Sodium Chloride | 35 | $98 |
| Diphenhydramine Hcl | 17 | $26 |
Paid to pharmacies, not to this prescriber.
Other neurology in Philadelphia
- Daniel KremensPhiladelphia$1.8M
- Thomas LeistPhiladelphia$1.4M
- Jill Giordano FarmerPhiladelphia$1.2M
- Stephanie Nahas-GeigerPhiladelphia$786K
- Amit Bar-OrPhiladelphia$596K
- Stephen SilbersteinPhiladelphia$428K
- Joseph BergerPhiladelphia$384K
- Sami KhellaPhiladelphia$285K
- Clyde MarkowitzPhiladelphia$274K
- Matthew SternPhiladelphia$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.